

Title (en)
PROCESS FOR PRODUCING PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS, AND THE USE OF SAME IN BREATHING DISORDER THERAPY

Title (de)
VERFAHREN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN DARREICHUNGSFORMEN ENTHALTEND INHIBITOREN VON TASK-1 UND TASK-3 KANÄLEN UND DEREN VERWENDUNG FÜR DIE THERAPIE VON ATEMSTÖRUNGEN

Title (fr)
PROCÉDÉ DE FABRICATION DE FORMES PHARMACEUTIQUES CONTENANT DES INHIBITEURS DES CANAUX TASK-1 ET TASK-3 ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES RESPIRATOIRES

Publication
EP 3886806 A1 20211006 (DE)

Application
EP 19805677 A 20191120

Priority
• EP 18208601 A 20181127
• EP 2019081950 W 20191120

Abstract (en)
[origin: WO2020109109A1] The invention relates to a process for producing pharmaceutical dosage forms containing potent and selective TASK-1 and/or TASK-3 channel inhibitors, and to the use of the dosage forms obtained by said production process to treat and/or prevent breathing disorders including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring.

IPC 8 full level
A61K 9/00 (2006.01); **A61K 9/08** (2006.01); **A61K 31/496** (2006.01); **A61K 47/10** (2017.01)

CPC (source: EP IL KR US)
A61K 9/0043 (2013.01 - EP IL KR US); **A61K 9/08** (2013.01 - EP IL KR); **A61K 31/496** (2013.01 - EP IL US); **A61K 31/4995** (2013.01 - US); **A61K 31/506** (2013.01 - EP IL); **A61K 31/519** (2013.01 - KR); **A61K 47/10** (2013.01 - EP IL KR US); **A61K 47/26** (2013.01 - KR US); **A61P 11/00** (2018.01 - KR)

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2020109109 A1 20200604; AU 2019389215 A1 20210610; BR 112021008153 A2 20210803; CA 3120775 A1 20200604; CL 2021001359 A1 20211105; CN 113194924 A 20210730; CN 113194924 B 20240712; CO 2021006814 A2 20210610; CR 20210277 A 20210707; DO P2021000105 A 20210722; EA 202191480 A1 20210827; EC SP21036326 A 20210630; EP 3886806 A1 20211006; GE P20247606 B 20240311; IL 283324 A 20210729; JO P20210121 A1 20230130; JP 2022508217 A 20220119; JP 7474760 B2 20240425; KR 20210095898 A 20210803; MA 54275 A 20220302; MX 2021006081 A 20210706; PE 20211285 A1 20210719; PH 12021551186 A1 20211103; SA 521422114 B1 20231221; SG 11202105551Y A 20210629; US 2021393624 A1 20211223

DOCDB simple family (application)
EP 2019081950 W 20191120; AU 2019389215 A 20191120; BR 112021008153 A 20191120; CA 3120775 A 20191120; CL 2021001359 A 20210525; CN 201980077910 A 20191120; CO 2021006814 A 20210524; CR 20210277 A 20191120; DO 2021000105 A 20210527; EA 202191480 A 20191120; EC DI202136326 A 20210521; EP 19805677 A 20191120; GE AP2019015674 A 20191120; IL 28332421 A 20210520; JO P20210121 A 20191120; JP 2021529444 A 20191120; KR 20217019408 A 20191120; MA 54275 A 20191120; MX 2021006081 A 20191120; PE 2021000753 A 20191120; PH 12021551186 A 20210524; SA 521422114 A 20210526; SG 11202105551Y A 20191120; US 201917296914 A 20191120